Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy
RegulatoryapprovedPasatruPositive
AI Analysis
Summary
Regeneron received FDA approval for Pasatru, a therapy for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. The approval drove Regeneron's stock up 5.4%.
Outcome Details
FDA approval of Pasatru for ultra-rare FOP therapy
Importance:8/10
Sentiment:
0.90
FDA approvalrare diseaseFOPorphan drug
Related Companies
Read the original article
Published by yahoo_finance on August 20, 2026 5:10 AM